Factors | PD-L1-positive (n = 25) | PD-L1-negative (n = 36) | p-value |
---|---|---|---|
Age (years old; median ± SD) | |||
68 ± 11 | 64 ± 17 | 0.268 | |
Menopausal status | |||
premenopausal | 1 | 8 | 0.067 |
postmenopausal | 24 | 27 | |
unknown | 0 | 1 | |
Tumour size (mm) | |||
≤ 20 | 11 | 20 | 0.440 |
> 20 | 14 | 16 | |
Pathological stage | |||
I + II | 21 | 32 | 0.706 |
III | 4 | 4 | |
Lymph node status | |||
positive | 6 | 8 | 0.534 |
negative | 18 | 15 | |
not tested | 1 | 13 | |
Lymphatic invasion | |||
positive | 22 | 30 | 0.725 |
negative | 3 | 6 | |
Venous invasion | |||
positive | 15 | 22 | 1.000 |
negative | 10 | 14 | |
Nottingham histlogical grade | |||
1 + 2 | 11 | 18 | 0.795 |
3 | 14 | 18 | |
Ki-67 labeling index (LI) | |||
high | 13 | 15 | 0.792 |
low | 12 | 17 | |
not tested | 0 | 4 | |
Stromal TILs | |||
LPBC | 12 | 7 | 0.025 |
non-LPBC | 13 | 29 | |
PD-L1 on stromal TILs (E1L3N) | |||
positive | 12 | 3 | < 0.001 |
negative | 13 | 32 | |
not tested | 0 | 1 | |
Adjuvant chemotherapy | |||
performed | 12 | 22 | 0.784 |
not performed | 10 | 14 | |
undetermined | 3 | 0 |